Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Retained Earnings (2018 - 2025)

Dna X (SONM) has disclosed Retained Earnings for 8 consecutive years, with -$295.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 12.74% year-over-year to -$295.4 million, compared with a TTM value of -$295.4 million through Sep 2025, down 12.74%, and an annual FY2024 reading of -$283.6 million, down 13.46% over the prior year.
  • Retained Earnings was -$295.4 million for Q3 2025 at Dna X, down from -$290.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$205.5 million in Q1 2021 and bottomed at -$295.4 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$252.0 million, with a median of -$249.6 million recorded in 2023.
  • The sharpest move saw Retained Earnings fell 19.69% in 2021, then grew 0.09% in 2023.
  • Year by year, Retained Earnings stood at -$234.8 million in 2021, then decreased by 6.42% to -$249.9 million in 2022, then fell by 0.04% to -$250.0 million in 2023, then fell by 13.46% to -$283.6 million in 2024, then dropped by 4.15% to -$295.4 million in 2025.
  • Business Quant data shows Retained Earnings for SONM at -$295.4 million in Q3 2025, -$290.6 million in Q2 2025, and -$283.2 million in Q1 2025.